Researcher
Karl Dhaene
- Keywords:Medicine
- Disciplines:Natural sciences
Affiliations
- Supporting clinical sciences (Department)
Member
From1 Oct 2017 → 30 Sep 2020 - Supporting clinical sciences (Department)
Member
From1 Oct 2017 → 30 Sep 2020 - Experimental Pathology (Research group)
Member
From30 Mar 2017 → 30 Sep 2020 - Pathology (Department)
Member
From1 May 2015 → 30 Apr 2018
Publications
1 - 10 of 10
- A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus(2019)
Authors: O Türeci, Ugur Sahin, H Schulze-Bergkamen, Z Zvirbule, F Lordick, D Koeberle, P Thuss-Patience, T Ettrich, Douglas L Arnold, F Bassermann, et al.
Pages: 1487-1495 - A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer(2018)
Authors: Ugur Sahin, Martin Schuler, Heike Richly, Stefan Bauer, Anna Krilova, Tobias Dechow, Markus Jerling, Magdalena Utsch, Christoph Rohde, Karl Dhaene, et al.
Pages: 17-26 - Prostatic Leiomyoma(2016)
Authors: Annelies Ringoir, Bernard Rappe, Karl Dhaene, Denis Schallier
Pages: 45-47 - Pathological diagnosis and molecular testing in non-small cell lung cancer: Belgian guidelines(2016)
Authors: Patrick Pauwels, M. Remmelink, D Hoton, J. Van Dorpe, Karl Dhaene, F dome, A. Jouret-Mourin, B Weynand, N D Haene
Pages: 123-131 - Functional TCR retrieval from single antigen-specific human T cells reveals multiple novel epitopes(2014)
Authors: Petra Simon, Tana A Omokoko, Andrea Breitkreuz, Lisa Hebich, Sebastian Kreiter, Sebastian Attig, Abdo Konur, Cedrik M Britten, Claudia Paret, Karl Dhaene, et al.
Pages: 1230-1244 - Claudin 18.2 is a target for IMAB362 antibody in pancreatic neoplasms(2014)
Authors: Stefan Wöll, Anna Melissa Schlitter, Karl Dhaene, Marc Roller, Irene Esposito, Ugur Sahin, Özlem Türeci
Pages: 731-739 - Claudin-18 gene structure, regulation, and expression is evolutionary conserved in mammals(2011)
Authors: Ozlem Türeci, Michael Koslowski, Gerd Helftenbein, John Castle, Christoph Rohde, Karl Dhaene, Gerhard Seitz, Ugur Sahin
Pages: 83-92 - Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development(2008)
Authors: Ugur Sahin, Michael Koslowski, Karl Dhaene, Dirk Usener, Gunda Brandenburg, Gerhard Seitz, Christoph Huber, Ozlem Türeci
Pages: 7624-7634 - MS4A12 is a colon-selective store-operated calcium channel promoting malignant cell processes(2008)
Authors: Michael Koslowski, Ugur Sahin, Karl Dhaene, Christoph Huber, Ozlem Türeci
Pages: 3458-3466 - In silico strategy for detection of target candidates for antibody therapy of solid tumors(2008)
Authors: Gerd Helftenbein, Michael Koslowski, Karl Dhaene, Gerhard Seitz, Ugur Sahin, Ozlem Türeci
Pages: 76-84